Amexdrug Corporation (AXRX) Stock Price & Analysis
Amexdrug Corporation (AXRX) — price $0.0002 (0.00%), as of the Nov 18, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Amexdrug Corporation · AXRX
The company also engages in R&D, manufacturing, and sale of drugs, cosmetics, and medical devices, with a focus on its Sponix brand and private labeling services.
Price as of Nov 18, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.0002 |
| Change on the day | 0.00% |
| Price / earnings (trailing) | 1.00 |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for Amexdrug (AXRX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Amexdrug (AXRX), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Amexdrug Corporation (AXRX) is the company analyzed here. It employs 9 people. In Q1 FY2026 it reported revenue of $736,558 and net income of $20,973.
What do the latest results show for Amexdrug (AXRX)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $736,558.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $736,558 | $20,973 | $0.0001 (diluted) |
| Q4 FY2025 | $700,749 | -$16,616 | $0.00 (diluted) |
| Q3 FY2025 | $679,484 | $9,987 | $0.0001 (diluted) |
| Q2 FY2025 | $754,641 | $31,343 | $0.0002 (diluted) |
What are the financial strengths and risks for Amexdrug (AXRX)?
Short answer · as of
Trailing ratios: ROE 2.5% · ROA 1.9% · current ratio 15.30 · earnings yield 134.8%.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 1
- Identified insiders
- 1
- Purchases
- 0
- Sales
- 0
- Other transactions
- 1
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held AXRX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported AXRX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Amexdrug (AXRX)
These answers are editorial: 1 of these 1 answer is drawn from the AXRX research dossier (written Jun 15, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.
How does Amexdrug Corporation generate revenue through its two primary divisions?
Amexdrug Corporation generates revenue through two distinct operational divisions: Distribution and Health and Beauty Products. The Distribution division focuses on the wholesale supply of pharmaceutical products, including prescription and over-the-counter medications, along with various non-drug and health and beauty essentials.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 11 figures on this page — 10 from Financial Modeling Prep (FMP) and 1 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com